Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Par-4 Overexpression Impedes Leukemogenesis in the Eµ-TCL1 Leukemia Model

Joseph Thomas Greene, BS, Rahul Ramaswamy, Mary K McKenna, BS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Ronni Wasmuth, BS, Minh Tran, BS, Xiaokui Mo, PhD MAS, Carlo M. Croce, MD, Vivek Rangnekar, PhD, John C. Byrd, MD, Subbarao Bondada, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1223.

https://doi.org/10.1182/blood.V130.Suppl_1.1223.1223

Published: 2017

Journal Articles

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Xiaokui Mo, PhD MAS, Pearlly S. Yan, PhD, Michael B Broe, PhD, Ralf Bundschuh, PhD, Larry State Beaver, Kevan Zapolnik, BS, Zhiliang Xie, Donna Bucci, David M. Lucas, PhD, Allison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Ching-Shih Chen, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MDMBBS, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1247.

https://doi.org/10.1182/blood.V130.Suppl_1.1247.1247

Published: 2017

Journal Articles

Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eileen Hu, BS, Priscilla Do, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Haiyong Peng, PhD, Lorenz Waldmeier, PhD, Roger Beerli, PhD, Christoph Rader, PhD, Ulf Grawunder, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 3017.

https://doi.org/10.1182/blood.V130.Suppl_1.3017.3017

Published: 2017

Journal Articles

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Chi-Ling Chiang, MS, Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Zhiliang Xie, Xiaomeng Huang, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, PhD, Mitch A. Phelps, PhD, Guido Marcucci, MD, John C. Byrd, MD, James L. Lee, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 4981.

https://doi.org/10.1182/blood.V130.Suppl_1.4981.4981

Published: 2017

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Chi-Ling Chiang, Frank W Frissora, Zhiliang Xie, Xiaomeng Huang, Rajeswaran Mani, DVM, Sivasubramanian Baskar, Christoph Rader, Kenneth K. Chan, Guido Marcucci, MD, John C. Byrd, MD, L. James Lee, Natarajan Muthusamy, DVM, PhD

Blood (2015) 126 (23): 1743.

https://doi.org/10.1182/blood.V126.23.1743.1743

Published: 2015

Journal Articles

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Rajeswaran Mani, DVM, Yicheng Mao, PhD, Frank W Frissora, M.S., Chi-ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ph.D., Ribai Yan, Xiaokui Mo, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D., Mitch A. Phelps, PhD, Robert J. Lee, Ph.D, Ching-Shih Chen, PhD, James Lee, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 4168.

https://doi.org/10.1182/blood.V122.21.4168.4168

Published: 2013

Journal Articles

Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,

Lapo Alinari, MD., Ph.D., Ryan B. Edwards, Courtney J. Prince, William H. Towns, Rajeswaran Mani, DVM, Amy Lehman, Xiaoli Zhang, PhD, MS, David Jarjoura, PhD, Li Pan, PhD, A. Douglas Kinghorn, PhD, DSc, Michael R. Grever, M.D., Robert A. Baiocchi, M.D., Ph.D., David M. Lucas, PhD

Blood (2011) 118 (21): 3498.

https://doi.org/10.1182/blood.V118.21.3498.3498

Published: 2011

Journal Articles

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

Lapo Alinari, MD., Ph.D., Emilia Mahoney, MD, PhD, John T. Patton, Xiaoli Zhang, PhD, MS, Lenguyen Huynh, Christian Tyler Earl, Rajeswaran Mani, DVM, Yicheng Mao, Bo Yu, Ph.D., William H. Towns, Ching-Shih Chen, Ph.D, David M. Goldenberg, Kristie A. Blum, MD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Mette Ibba, PhD, Robert A. Baiocchi, M.D., Ph.D.

Blood (2011) 118 (21): 600.

https://doi.org/10.1182/blood.V118.21.600.600

Published: 2011

Journal Articles

OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase

Rajeswaran Mani, DVM, Frank W Frissora, M.S., Ching-Shih Chen, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2011) 118 (21): 2499.

https://doi.org/10.1182/blood.V118.21.2499.2499

Published: 2011

NARROW

Par-4 Overexpression Impedes Leukemogenesis in the Eµ-TCL1 Leukemia Model

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only